The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo

Overview of attention for article published in BMC Cancer, January 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,018 followers.

RT @BjoernBruecher: R-ketorolac inhibits Cdc42 & Rac1 Grimes et al. BMC Cancer 2021 decreasing -HIF-1 signaling -cell proliferation -adhes…

15 Jan 2021

Reply Repost Favourite

RT @BjoernBruecher: R-ketorolac inhibits Cdc42 & Rac1 Grimes et al. BMC Cancer 2021 decreasing -HIF-1 signaling -cell proliferation -adhes…

15 Jan 2021

Reply Repost Favourite

R-ketorolac inhibits Cdc42 & Rac1 Grimes et al. BMC Cancer 2021 decreasing -HIF-1 signaling -cell proliferation -adhesion -migration while S-enantiomere is inactive against GTPases R-ketorolac=(1R)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic a

15 Jan 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.